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Abstract
Using digital microfluidics, recombinant enzyme technology, and magnetic nanoparticles, we have
created a functional prototype of an artificial Golgi organelle. Analogous to the natural Golgi, which
is responsible for the enzymatic modification of glycosaminoglycans immobilized on proteins, this
artificial Golgi enzymatically modifies glycosaminoglycans, specifically heparin sulfate (HS) chains
immobilized onto magnetic nanoparticles. Sulfo groups were transferred from adenosine 3′-
phosphate 5′-phosphosulfate to the 3-hydroxyl group of the D-glucosamine residue in an immobilized
HS chain using D-glucosaminyl 3-O-sulfotransferase. After modification, the nanoparticles with
immobilized HS exhibited increased affinity for fluorescently labeled antithrombin III as detected
by confocal microscopy. Since the biosynthesis of HS involves an array of specialized glycosyl
transferases, epimerase, and sulfotransferases, this approach should mimic the synthesis of HS in
vivo. Furthermore, our method demonstrates the feasibility of investigating the effects of multi-
enzyme systems on the structure of final glycan products for HS-based glycomic studies.
Introduction
The Golgi organelle, discovered in 1898 by Camillo Golgi, remains one of the most poorly
understood organelles in the human cell. This organelle is central to the posttranslational
modification of proteins, the new frontier in the field of glycomics. It is estimated that the
majority of human proteins are posttranslationally modified within the Golgi,1 primarily
through glycosylation, and that these modifications are critical for protein function and
stability.
Heparan sulfate (HS) glycosylation of proteoglycans (PGs) takes place in the Golgi organelle
(Figure 1a). Linear, O-linked glycosaminoglycan (GAG) chains composed of repeating
glucuronic acid and N-acetylglucosamine residues are attached to the serine residues of a core
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protein through a linkage region to form a PG and are sequentially modified by a series of
biosynthetic enzymes including an N-deacetylase/N-sulfotransferase (NDST), C5 epimerase,
and 2-, 6-, and 3-O-sulfotransferases (2-OST, 6-OST and 3-OST, respectively). NDST
catalyzes the N-deacetylation/N-sulfonation of the glucosamine residues, C5 epimerase
converts glucuronic acid into iduronic acid, and 2-OST, 6-OST, and 3-OST catalyze the O-
sulfonation of the 2-O-position of the uronic acid, and the 6-O and 3-O-positions of the
glucosamine unit, respectively.2,3 There is also an alternative theory of GAG biosynthesis that
suggests the concerted action between one or more of the biosynthetic enzymes.4
Many of these modifications in the Golgi are only partially complete, resulting in a large
number of sequence permutations, dramatically complicating the structure of HS.4 The
ensemble of the GAG chains afforded contain different and often unique structural features
that determine their protein binding specificity and ultimate biological activity. PGs
synthesized with specific GAG chains are found in the extracellular matrix, and on the surface
of mammalian cells. They are involved in important physiological and pathophysiological
processes including blood coagulation, infection, cellular growth and differentiation, tumor
metastasis, and angiogenesis.5
It is believed that the structure of the Golgi apparatus contributes to the structure of HS.
Unfortunately, the complexity of the Golgi apparatus limits our understanding of HS
biosynthesis. Because studying the in vitro enzymatic synthesis of HS in the absence of a Golgi
structure cannot permit a full understanding of the control and regulation of HS biosynthesis,
we undertook the design and fabrication of an artificial Golgi using a digital microfluidic
platform (Figure 1b) that resembles the natural organelle. This work represents the first step
toward the creation of such a biomimetic organelle.
Microfluidics and lab-on-a-chip technologies enable reactions on the micro- and nanoscales,
reducing reagent consumption and analysis time, increasing reaction control and throughput,
and providing opportunities for full automation.6 Two types of microfluidic systems have been
developed: 1) channel microfluidics, which involves fluid flow in patterned channels,; and 2)
digital microfluidics, wherein open droplet movement occurs through the process of
electrowetting on a 2D grid-like platform. Digital microfluidics has gained popularity by
eliminating many of the constraints associated with fixed channels7 and allowing individual
droplets in a biochemical array to be addressed. Some previous applications of digital
microfluidics include glucose and other enzyme-based assays, preparation of protein samples
for matrix-assisted laser desorption/ionization mass spectrometry, polymerase chain reaction,
and cell-based assays.8
Digital microfluidics chips consist of an array of electrodes (Figure 1c) coated with an insulator
followed by a hydrophobic layer (Figure 1d). Droplet movement in digital microfluidics is
driven by electrowetting, the ability of a surface to tune its wettability by the application of
electrical pulses. To operate a digital microfluidic device, a droplet of fluid is placed over one
electrode and then a voltage is applied to an adjacent electrode, causing the insulator above
that electrode to become charged. This makes the destination electrode more hydrophilic
causing the droplet to move.9 This wettablity of the surface is reversible, thus allowing the
droplet to be moved to an adjacent electrode of choice. In this manner, sample-containing
droplets may be transported, mixed, and separated on the chip.
The current study investigates the modification of HS by D-glucosaminyl 3-O-sulfotransferase
isoform-1 (3-OST-1) using digital microfluidics to afford an HS with an increased affinity for
anticoagulant protein antithrombin III (ATIII). This represents a first step towards the
construction of an artificial Golgi organelle that may serve as a test-bed to better understand
how the natural Golgi controls the biosynthesis of GAGs.
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Microfluidic chips were fabricated using standard clean room processes at Rensselaer’s Center
for Integrated Electronics Micro and Nano Fabrication Clean Room using a modified clean
room process from Wheeler et al.10 Briefly, chips were designed using Macromedia Freehand
(San Jose, CA) with standard dimensions of: electrode size (1 mm × 1 mm), reservoir size (3
mm × 3 mm), and electrode spacing (5 μm). Photomask transparencies constructed from these
designs were made by M & J Prepress (Albany, NY). Glass slides (Thermo Fisher Scientific,
Waltham, MA) were cleaned with piranha solution (7:3 concentrated sulfuric acid/30%
hydrogen peroxide, 10 min), followed by coating with 10 nm of chromium (International
Advanced Materials, Spring Valley, NY), and 100 nm of gold (International Advanced
Materials Spring Valley, NY) by electron beam deposition. The slides were then rinsed with
acetone, methanol, and DI water and baked on a hotplate at 115°C for 5 min. Substrates were
spin coated with photoresist and exposed through a photomask using a Karl Suss mask aligner
(Garching, Germany). The exposed substrates were developed in AZ300MIF (AZ Electronic
Materials, Branchburg, NJ) for 3 min and post-baked on a hotplate. The remaining unexposed
gold and chromium was then etched away. The remaining photoresist was stripped in AZ300T
(AZ Electronic Materials, Branchburg, NJ) for 5 min in an ultrasonic bath. The chips were then
coated with 2 μm parylene C followed by spin-coating with a 1% Teflon AF solution in FC-40
(DuPont, Wilmington, DE) at 2000 rpm for 1 min. The extra solvent was then evaporated by
placing the chip on a hotplate at 160°C for 10 min. Indium-tin-oxide coated glass slides (Delta
Technologies, Stillwater, MN) were also coated with a 1% Teflon AF solution and used as
coverslips.
Chip operation
Electrical equipment used for chip operation included an Agilent 33220A 20 MHz Function/
Arbitrary Waveform Generator (Santa Clara, CA) and a Trek Model PZD700 Dual Channel
Amplifier (Medina, NY). Four basic droplet operations for digital microfluidic devices were
used in this study: 1) droplet actuation; 2) dispensing; 3) splitting; and 4) mixing. Droplet
actuation was achieved by applying an AC voltage 50 – 100 VRMS to a destination electrode
adjacent to the droplet. Sample droplets were dispensed from reservoir droplets by applying
voltage to electrodes adjacent to the reservoir to draw a portion of the droplet away from the
reservoir while holding the remaining bulk of the droplet within the reservoir using a separate
application of voltage. After a distance of about two electrodes, surface tension caused splitting
of the sample droplet from the reservoir droplet. Droplets were split by application of voltage
to the electrodes adjacent to the ends of the droplet and maintaining the voltage until the
splitting occurred. Droplets were mixed by actuating two droplets to the same electrode then
homogenized by pulsing voltage to the electrodes adjacent to the ends of the droplet to cause
stretching.
Immobilization of heparan sulfate onto magnetic nanoparticles
Sodium HS from porcine intestinal mucosa was obtained from Celsius Laboratories
(Cincinnati, OH). The HS was first completely N-acetylated at 25°C by dissolving 200 mg of
HS in 10 mL 0.05 M sodium carbonate (Sigma-Aldrich, St. Louis, MO) containing 10%
methanol (Sigma-Aldrich, St. Louis, MO) and adding 80 μL acetic anhydride (Sigma-Aldrich)
dropwise over a period of 2 h. The solution containing N-acetylated HS was then diluted with
two volumes of distilled water, dialyzed (2,000 molecular weight cut-off (MWCO)) for 48 h
and lyophilized. This fully N-acetylated heparin (100 mg) was dissolved in formamide (8.3
μM) (Sigma-Aldrich) at 50°C, 2,6-diaminopyridine (100 mg) (Sigma-Aldrich) was added, and
the reaction mixture was maintained at 50°C for 3 h. Sodium cyanoborohydride (19 mg)
(Sigma-Aldrich) was added and the mixture was maintained at 50°C for 24 h, diluted with 20
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mL of water, dialyzed (2,000 MWCO) exhaustively for 48 h, and lyophilized. The lyophilized
diaminopyridylinylated HS was further purified by SAX chromatography followed by
methanol precipitation.11 The resulting 2,6-diaminopyridinyl heparin was dissolved in
phosphate buffered saline (PBS, pH 7.4) and a 20-fold molar excess of Sulfo-NHS-PEG-Biotin
(5000 MW) (Nanocs, New York, NY) was added. The reaction mixture was incubated at 25°
C for 1 h and then dialyzed (3,000 MWCO) to remove excess biotin. The retentate containing
biotinylated HS was then lyophilized.
Using a magnetic rack (New England Biolabs, Ipswitch, MA), streptavidin magnetic
nanoparticles (600 nm diameter) from MagnaMedics Diagnostics (Maastricht, The
Netherlands) were washed with 0.05% Triton X-100 (Sigma-Aldrich) in PBS. Biotiylated HS
was added (3-fold molar excess) to the solution of streptavidin magnetic nanoparticles and the
mixture was incubated on a roller mixer at 25°C for 45 min. The nanoparticles were then
washed extensively with 0.05% Triton X-100 in PBS to remove the excess biotinylated HS.
The nanoparticles were further washed with PBS buffer to remove the Triton X-100 surfactant.
The overall immobilization scheme is shown in Figure 2.
Quantification of heparan sulfate on magnetic nanoparticles by enzymatic digestion
HS-nanoparticles (1 mg) were incubated with 25 milliunits each of a mixture of heparin lyase
1, 2, and 3 for 24 h at 37°C to quantify the amount of HS that had been immobilized. After 24
h, the nanoparticles were isolated using the magnetic rack and the supernatant was recovered
by decanting. The supernatant, containing heparin lyases and HS disaccharides, was passed
through a 3,000 MWCO spin column (PALL, East Hills, NY) to recover the free HS
disaccharides from the enzymes. A microscale carbazole assay was used to determine the
amount of free disaccharides present from which the amount of enzyme accessible immobilized
HS chains could be calculated.
Quantification of modification of heparan sulfate on nanoparticles by 3-OST
Recombinant 3-OST-1 enzyme was prepared as previously described12 and adenosine 3′-
phosphate 5′-phosphosulfate (PAPS) was obtained from Sigma-Aldrich (St. Louis, MO).
[35S]PAPS was prepared from ATP and sodium [35S] sulfate in the presence of yeast extract
(from Sigma-Aldrich).13 Immobilized HS (about 20 μg) was incubated with purified 3-OST-1
(300 μg) and PAPS (100 μM) in 300 μL of reaction buffer containing 50 mM MES (pH 7.0),
1 mM MgCl2, and 2 mM MnCl2. The reaction was shaken at 30 °C at 200 RPM for 2 h. The
nanoparticles were then washed with 3 × 1 mL of 250 mM NaCl followed by 3 × 1 mL of 1
M NaCl. An identical reaction was carried out by replacing unlabeled PAPS with 35S-labeled
PAPS to estimate the degree of 3-O-sulfonation. The degree of 3-O-sulfonation was estimated
by measuring 35S-radioactivity on the nanoparticles. A time course reaction was carried out
by incubating immobilized HS (50 μg) with purified 3-OST-1 (100 μg) and [35S]PAPS at 30
°C. The reaction was stopped periodically and an aliquot was removed, and the beads were
washed with buffer containing 3 M urea followed by buffer with 1 M NaCl. The washed beads
were then mixed with scintillation fluid to determine the level of incorporation of 35S-label.
Synthesis of Fluorescently labeled ATIII
Amine reactive 4,4-Difluoro-5-phenyl-4-bora-3,4a-diaza-s-indacene-3-propionic acid,
succinimidyl ester (BODIPY® R6G, SE) was obtained from Invitrogen Corporation (Carlsbad,
CA). ATIII was obtained from Aniara (Mason, OH). BODIPY® R6G dye was covalently
attached to ATIII. ATIII (10 mg) was dissolved in 1 mL of 0.1 M sodium bicarbonate buffer
and BODIPY® R6G (5 mg) was dissolved in 0.5 mL anhydrous DMF (Sigma-Aldrich, St.
Louis, MO). BODIPY® R6G (100 μL) was added with stirring to the ATIII solution. The
reaction mixture was incubated for 1 h at room temperature with continuous stirring. After the
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completion of the reaction, a 3,000 MWCO spin column was used to remove excess BODIPY®
R6G. The purified BODIPY® R6G labeled ATIII was then stored at −20°C.
Off-chip enzymatic modification
PAPS and 3-OST-1 were mixed with nanoparticles in PBS then washed with distilled water
as described above. The 3-OST-1 modified nanoparticles (100 μg) were incubated at 25 °C
with BODIPY® R6G labeled ATIII (1 μg) in 10 mL of 2.5-fold concentrated PBS containing
0.025% Tween X-100 for 30 min. After incubation, the nanoparticles were washed with 0.05%
Tween X-100 in 5-fold concentrated PBS then distilled water. The nanoparticles were imaged
using a Zeiss LSM 510 META confocal microscope with a 100X/1.45 oil objective (Zeiss,
Jena, Germany). A 514 nm argon laser was used to excite BODIPY® R6G and a 530 nm –
600 nm emission filter was used. A range check pseudocolored map was used to optimize the
dynamic range for the images.
On-chip enzymatic modification
Two droplets, one containing 400 nL of 3-OST-1 (0.1 mg/mL) and PAPS (25 μM) in PBS and
the second containing nanoparticle-immobilized HS (5 mg/mL) in PBS, were loaded onto a
digital microfluidics chip into a layer of 1.0 cSt silicone oil (Gelest, Morrisville, PA) containing
0.1% Triton® X-15 (Sigma-Aldrich, St. Louis, MO). The use of silicon oil and the short
duration of electrode activation reduced non-specific adsorption of protein to the surface and
droplet heating. The chip was used to drive the droplets to the mixing area and perform the
mixing operation by first joining the two droplets then stretching the droplet to homogenize
the reaction mixture. Following the mixing operation, the reaction droplet was incubated at
room temperature for 1 h with an additional homogenizing step at 30 min. Based on the results
of the 3-OST-1 time course experiment (see Supporting Information Figure S1), an on-chip
incubation time of 1 h was selected to allow for at least one 3-O-sulfonation site per HS chain,
as is present in the natural polysaccharide. After the incubation was complete, the droplet was
recovered using a micropipette added to an 800 nL droplet of water following addition of a
400 nL droplet containing fluorescent ATIII (0.175 mg/mL) and 0.0375% Tween 100 in 3.75-
fold concentrated PBS. The 3-OST-1 modified HS-nanoparticles were incubated with
fluorescent ATIII at room temperature for 30 min. After incubation, the nanoparticles were
washed with 0.05% Tween X-100 in 5-fold concentrated PBS then distilled water. The
nanoparticles were imaged using a Zeiss LSM 510 META confocal microscope with a 100X/
1.45 oil objective (Zeiss, Jena, Germany). A 514 nm argon laser was used to excite BODIPY®
R6G and a 530 nm – 600 nm emission filter was used. A range check pseudocolored map was
used to optimize the dynamic range for the images. Control experiments were also conducted
using a 400 nL droplet of PBS in place of the 3-OST-1 enzyme in PBS.
Analysis of confocal images
Transmitted bright field images acquired from confocal microscopy were imported in to Adobe
Photoshop (Adobe Systems Incorporated, San Jose, CA) where the background was selected
and filled with white. The images were then imported into ImageJ (National Institutes of
Health, Bethesda, MD) and converted to 16-bit grayscale. The ImageJ analyze particle feature
was used to determine the total area of the nanoparticles. Next, the confocal fluorescence
images were converted to 16-bit grayscale images and imported into ImageJ. The images were
processed using the despeckle feature and all pixels of low intensity (2 out of 255 or lower)
were ignored to remove noise. The analyze particle feature in ImageJ was used to determine
the total area of the fluorescent ATIII on the nanoparticles. The total area was then used to
calculate the percent coverage of fluorescent ATIII on the nanoparticles.
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Immobilization and functional properties of heparan sulfate bound to magnetic nanoparticles
Biotinylated HS was successfully prepared and immobilized onto streptavidin coated magnetic
nanoparticles (Figure 2). The amount of enzyme-accessible HS, determined using heparinase,
was 2.7 μg/mg of nanoparticles. This amount reflects the minimum amount biotinylated HS
attached to the nanoparticles, which represents only the enzyme-accessible HS.
The activity of 3-OST-1 on HS-linked nanoparticles was determined using [35S]PAPS and
scintillation counting. 3-OST-1 (120 μg) catalyzed the transfer of 4 pmol of 3-O-sulfo groups
to 8.1 μg of HS linked to nanoparticles (Figure 2), which elevated the 35S-radioactivity of the
enzymatically modified particles to ~ 70-fold above the control (absence of 3-OST-1 enzyme).
This corresponded to the introduction of a 35S — sulfo group onto ~ 5% of the immobilized
HS chains. This value is expected based on the specificity of 3-OST-1 for the limited number
of modifiable domains present within HS.14
After confirming that HS immobilized onto the nanoparticles was capable of being modified
by 3-OST-1, we performed modification of immobilized HS on a new set of nanoparticles
without using radiolabeling. We then removed the 3-OST-1 from the reaction mixture by
precipitating the magnetic nanoparticles and incubated the modified nanoparticles with
fluorescent ATIII to investigate the binding properties of the 3-OST-1 modified immobilized
HS (Figure 3).
Using confocal microscopy, a pronounced increase in the binding of fluorescent ATIII was
observed following 3-OST-1 modification of immobilized HS on nanoparticles (Figure 4 and
Supporting Information Figure S2) as compared to unmodified immobilized HS on
nanoparticles (Figure 5 and Supporting Information Figure S2). The binding is specific to the
modified HS nanoparticles as clearly seen in Figure 4c, the overlay of the fluorescence image
(Figure 4a) and the transmitted bright field image (Figure 4b). Analysis using ImageJ software,
demonstrated that 32% of the surface area of the 3-OST modified HS nanoparticles bound
fluorescent ATIII (Figure 4, d & e and Figure 6), whereas only 0.5% of the surface area of the
control unmodified HS nanoparticles bound fluorescent ATIII (Figure 5, d & e and Figure 6).
On-chip modification of heparan sulfate on magnetic nanoparticles and subsequent protein
binding assay of modified heparan sulfate
The ability to detect ATIII binding resulting from 3-OST-1 catalyzed modification of HS
nanoparticles led us to perform on-chip reactions. Using the digital microfluidic chip, two
droplets - one containing 3-OST-1 (40 ng, 1 pmol) and PAPS cofactor (25 μM) and the second
containing HS immobilized onto nanoparticles (5.4 ng, 0.4 pmol) - were loaded onto the chip.
The chip was then used to drive the droplets to a mixing area by application of an AC voltage
of 50 – 100 VRMS to the electrode adjacent to the droplet. The droplets were able to move at
a rate of up to 3 electrodes per min, corresponding to about 3 mm per min. Once at the mixing
area, the droplets were merged by driving them to the same destination electrode (Figure 7, a-
c), followed by homogenizing the reaction droplet by applying voltage (Figure 7, d-f). The
reaction droplet was allowed to incubate on the chip for a period of 1 h with an additional
homogenizing step at 30 min to keep the nanoparticles in suspension. Following the reaction,
we performed a splitting of the reaction droplet to show the potential for additional reactions
to be performed in a combinatorial manner (Figure 7, g-i and Supporting Information Figure
S2), but then proceeded to rejoin the droplet. The droplets were then recovered from the chip,
incubated with fluorescent ATIII, washed to remove excess fluorescent ATIII, and observed
using confocal fluorescent microscopy (Figure 8). The results were similar to the experiments
performed off-chip (Figure 4) showing a significant increase in the ATIII binding affinity of
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the 3-OST-1 modified HS nanoparticles when compared to the unmodified control. Analysis
using ImageJ software, demonstrated that 30% of the surface area of the on-chip 3-OST
modified HS nanoparticles bound fluorescent ATIII (Figure 6 and Figure 8 d & e), whereas
only 0.5% of the surface area of the control unmodified HS nanoparticles bound fluorescent
ATIII (Figure 5 d & e and Figure 6). These results confirm that 3-OST-1 can be used to
successfully modify nanoparticle immobilized HS in a digital microfluidic system, resulting
in HS chains with high ATIII affinity.
Discussion
The loading of HS onto the magnetic nanoparticles was about 20 percent of the manufacturers
projected loading capacity, and can be explained by the large steric size of HS. According to
manufacturer’s specifications, the loading capacity of the streptavidin nanoparticles for the
small molecule of biotin-4-fluorescein (MW 645 Da) is 1000 pmol per mg of nanoparticles.
We measure a loading of about 200 pmol of HS (average MW 12500 Da) per mg of
nanoparticles based on an enzymatic digestion assay.
When the activity of 3-OST-1 on HS-linked nanoparticles was determined by [35S] PAPS and
scintillation counting, it was observed that the level of 3-O-sulfation was about 70-fold higher
on the 3-OST-1 modified nanoparticles compared to the control. Using these values we
calculated that 3-OST-1 catalyzed the introduction of a 35S —sulfo group to about 5% of the
immobilized HS chains. This value is low because not all HS chains contain an ATIII precursor
structure14 and 3-OST-1 may not have been able to access all of the immobilized HS, e.g.,
those buried from the surface of the exposed HS chains on the nanoparticles. However, even
though the sulfation level was low, there was still an easily measurable increase in HS’s binding
affinity for ATIII, as detected by confocal microscopy (Figures 4, 5 and 8). Results from the
on-chip and off-chip experiments were comparable; 32% of the surface area of the off-chip 3-
OST modified HS nanoparticles bound fluorescent ATIII and 30% of the surface area of the
on-chip 3-OST modified HS nanoparticles bound fluorescent ATIII (Figure 6). In the images
obtained, virtually all the beads from both on-chip and off-chip experiments showed bound
fluorescent ATIII (Figures 4 and 8c). As expected, not all of the surface area was covered with
fluorescent ATIII, as only 5% of the chains could be modified using 3-OST-1, based on steric
factors and the limited number of modifiable domains within HS. The control experiments
(Figure 5 and Supporting Information Figure S2) showed virtually no measureable
fluorescence associated with non-specific binding. Image analysis demonstrates experimental
(specific binding) is ~50-fold greater than control (non-specific binding) (Figure 6).
In summary, this work represents a first step toward the construction of an artificial Golgi
organelle through the use of digital microfluidics, recombinant enzyme technology, and
magnetic nanoparticles. HS was successfully immobilized onto magnetic nanoparticles and
enzymatically modified using 3-OST-1 in a droplet based digital microfluidic device. After
enzymatic treatment, the immobilized HS showed high affinity for fluorescent ATIII,
confirming its successful modification by 3-OST-1. This represents the first enzymatic
modification of an immobilized substrate in a digital microfluidic device and a critical first
step in the creation of an artificial Golgi. Work is currently underway to further develop the
artificial Golgi into a nano-scale lab-on-a-chip for the synthesis and screening of specific
glycans. Such an artificial Golgi will provide a platform for the high throughput synthesis of
small amounts of GAGs for biological and pharmacological evaluation. In addition, this tool
may be used as a test bed to design biosynthetic heparin, which could replace current unsafe
methods of heparin production from animal tissue.15
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The Golgi and an artificial Golgi. (a) A cartoon in which the Golgi of a eukaryotic cell is shown
in blue. The direction of flow (pink arrow) in posttranslational modification is from the ER
(red) to the cell membrane (yellow) where proteoglycans and glycoproteins are released into
the extracellular environment. (b) The design of an artificial Golgi for the biosynthesis of HS
is shown. Heparosan is modified by a series of biosynthetic enzymes including an N-
deacetylase/N-sulfotransferase (NDST), C5 epimerase, and 2-, 6-, and 3-O-sulfotransferases
(2-OST, 6-OST and 3-OST, respectively).3 Alternatively heparosan can be modified by using
a mixture of enzymes to explore the theory of concerted rather then sequential action of the
biosynthetic enzymes. The large boxes (multicolor) are reagents and enzyme reservoir
electrodes and the small boxes (light green) are electrodes for droplet movement, mixing, and
sequestration. (c) A fabricated artificial Golgi based on the design in panel b. The thin lines
are gold wires that lead to pads for connection to a power source used to drive the droplets. (d)
A diagram showing a cross-section of a droplet sitting over an electrode and overlapping two
adjacent electrodes. A glass coverslip on the top of the device contains the ground
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Chemistry used to immobilize HS substrate onto streptavidin magnetic nanoparticles and
subsequent 3-OST-1 modification. Unsubstituted amino groups are first N-acetylated and the
resulting HS is then reductively aminated with diaminopyridine to which NHS activated
PEG104-biotin is attached. The resulting glycoconjungate is then captured by streptavidin
magnetic nanoparticles (yellow) and modified by 3-OST-1, which catalyzes the 3-O-
sulfonation of HS using PAPS cofactor. During this reaction, the sulfo group (red circle) is
transferred from the PAPS cofactor to the glucosamine residue on the HS chain. To quantify
the level of 3-O-sulfonation, [35S]PAPS was used. Scintillation counting measured the transfer
of 1 pmol of 3-O-sulfo groups to every 2 μg of HS when immobilized to nanoparticles.
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Schematic of 3-OST-1 modification of immobilized HS on nanoparticles and subsequent
detection with fluorescently labeled ATIII taking place on the device shown in Figure 1c. A
magnet was used to selectively wash the nanoparticles in solution. The contents of the droplets
are labeled as followed (a) 3-OST-1 enzyme with PAPS (b) immobilized HS (c) Modification
of HS by 3-OST-1 (d) Removal of 3-OST-1, excess PAPS, and PAP (e) Modified HS (f)
Fluorescently labeled ATIII (g) Mixing of fluorescent ATIII with modified immobilized HS
(h) Excess fluorescently labeled ATIII removed from washing step (i) Fluorescence detection
of modified HS on nanoparticles.
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Confocal images and image analysis of HS nanoparticles modified off-chip with 3-OST-1 and
probed with fluorescent ATIII and washed. (a) Fluorescence image of ATIII bound to 3-OST-1
modified HS nanoparticles. (b) Transmitted bright field image of 3-OST-1 modified HS
nanoparticles (c) Overlay of (a) and (b). (d) Fluorescence area selected by ImageJ from (a)
shown in red. (e) Nanoparticle area selected by ImageJ from (b).
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Confocal images and image analysis of control unmodified HS nanoparticles probed with
fluorescent ATIII and washed. (a) Fluorescence image of ATIII bound to 3-OST-1 modified
HS nanoparticles. (b) Transmitted bright field image of 3-OST-1 modified HS nanoparticles
(c) Overlay of (a) and (b). (d) Fluorescence area selected by ImageJ from (a) shown in red. (e)
Nanoparticle area selected by ImageJ from (b).
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Graph comparing the percent coverage of fluorescent ATIII on unmodified HS nanoparticles,
3-OST-1 off-chip modified HS nanoparticles, and 3-OST-1 on-chip modified HS
nanoparticles. Both the off-chip and on-chip 3-OST-1 modified HS nanoparticles show a
significant increase in ATIII binding affinity when compared to the unmodified control. Error
bars are standard deviations based on n = 4.
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Video sequence of on-chip enzymatic modification of immobilized HS on nanoparticles by 3-
OST-1 enzyme. Time stamps in h:min:sec format. (a-c) Small circular droplet containing 3-
OST-1 enzyme and PAPS in PBS buffer (E) is joined with a small circular droplet containing
HS substrate immobilized on magnetic nanoparticles (S-B) in 1.13 s. (d-f) Large oval droplet
containing reaction components are mixed by stretching. (g-i) Large oval droplet can be split
into equal sized smaller circular droplets with one taken off chip for analysis and the other used
in secondary reactions.
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Confocal images and image analysis of HS nanoparticles modified on-chip with 3-OST and
probed with fluorescent ATIII and washed. (a) Fluorescence image of ATIII bound to 3-OST-1
modified HS nanoparticles. (b) Transmitted bright field image of 3-OST-1 modified HS
nanoparticles (c) Overlay of (a) and (b). (d) Fluorescence area selected by ImageJ from (a)
shown in red. (e) Nanoparticle area selected by ImageJ from (b).
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